Scaling team‑based, technology‑enabled care to improve diabetes control for adults with type 2 diabetes
Official title: Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
Run by Stanford University · NCT06251323 · Data updated 2026-11-12
This project will try a team-based, tech-enabled care program called iPATH to improve blood sugar control for adults with type 2 diabetes treated at federally qualified health centers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 119680 (estimated) |
| Sponsor | Stanford University Academic / other |
| Locations | 4 sites (Stanford, California and 3 other locations) |
| Status | Recruiting |
| Started | September 30, 2025 |
| Main results expected | July 1, 2027 |
| Study ends | January 31, 2028 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT06251323 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with type 2 diabetes who receive primary care at participating FQHC clinics—especially those served by clinics with below-average A1c control—are the intended participants.
✕Probably not a fit
Children, patients at clinics with very low diabetes prevalence, and people receiving care outside the selected FQHCs or regions are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Sixteen federally qualified health center (FQHC) clinic sites will be selected from HRSA data and followed for up to three years to measure changes in patient HbA1c. Eight clinics will begin the iPATH practice transformation in year one and the other eight will begin in year two, creating a staggered implementation for comparison. Clinic administrators, clinicians, and staff will participate in the transformation and take part in qualitative interviews and 12 in-depth regional case studies to identify organizational factors that help or hinder diabetes care. Patient HbA1c data will be collected annually to compare changes before and after implementation and between early and later adopters.
Why it matters
Potential benefit: If successful, iPATH could reduce average HbA1c and the proportion of patients with poorly controlled diabetes at participating FQHCs, improving long-term health outcomes for underserved populations.
How similar studies have gone: A prior pilot of the iPATH approach at seven clinics in Puerto Rico reported an average 31% reduction in the number of patients with A1c >9%, showing promising earlier results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Two largest clinic sites in multi-clinic FQHCs operating in or near Massachusetts, Ohio, California, Puerto Rico * We will prioritize FQHCs performing in the lower half of the distribution for A1c control, as these FQHCs have greater room for improvement. Exclusion Criteria: * FQHCs that have a patient population comprised of more than 80% children * FQHCs that have a patient population multiplied by the FQHC's diabetes prevalence in the lowest 10% of all the clinics * FQHCs that have fewer than 5,000 or more than 50,000 patients.
Where it's running
-
Board of Trustees of the Leland Stanford Junior University
Stanford, California, United States Recruiting -
President and Fellows of Harvard College, T.H. Chan School
Boston, Massachusetts, United States Recruiting -
The Ohio State University
Columbus, Ohio, United States Recruiting -
Impactivo, LLC.
San Juan, Puerto Rico, Puerto Rico Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.